Mylan, Company Behind EpiPen, Fought to Keep Cheaper Generic Off Market: Documents | NBC 6 South Florida
National & International News
The day’s top national and international news

Mylan, Company Behind EpiPen, Fought to Keep Cheaper Generic Off Market: Documents

    processing...

    NEWSLETTERS

    AP, File
    This Oct. 10, 2013, file photo, shows an EpiPen epinephrine auto-injector, a Mylan product, in Hendersonville, Texas. Mylan, now in the crosshairs over severe price hikes for its EpiPen, said Thursday, Aug. 25, 2016, it will expand programs that lower out-of-pocket costs by as much as half.

    The CEO of Mylan Pharmaceuticals announced the launch of its own cheaper version of the EpiPen this week on the heels of a price hike uproar. But for years, Mylan and its business partners have fought fiercely behind the scenes to block a cheaper generic from hitting the market, NBC New York's I-Team reported.

    Documents reviewed by the I-Team show the Pennsylvania-based drug firm paid for opposition research on a generic EpiPen proposed by Teva, an Israeli pharmaceutical company.

    The study concluded the Teva product would have a 93 percent failure rate.

    But experts on research methodology say the study has significant flaws, including the lack of any control group, the lack of any statistical significance, and the fact that study participants were instructed "not to actually manipulate the device or perform the injection."

    NC Santa Fired for Fat-Shaming Boy

    [NATL] Santa Fat-Shames Boy, Gets Fired, in North Carolina
    A North Carolina Santa Claus is on the naughty list and out of a job after he was accused of fat-shaming a little boy. The 9-year-old boys mother says that as he hopped down from Santa's lap in Forest City over the weekend, Santa told him to lay off the hamburgers and French fries, turning Christmas cheer into Christmas tears. (Published 4 hours ago)

    In an email to the I-Team, Nina Devlin, a company spokeswoman, defended the integrity of the study, saying it "offered a valid examination" of Teva's product design and how the injector might be used in an emergency.